Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

Plain-language summary

This study evaluates PF-05212384 (also known as PKI-587), given intravenously, in patients with solid tumors. It enrolled patients with incurable cancer that had progressed after at least one prior therapy with no further standard treatment available. The study was conducted in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Pfizer

Intervention

PF-05212384 (also known as PKI-587)

Start date

1/1/2010

Estimated completion

10/1/2012

Countries

United States, Spain, United Kingdom

Related genes

Locations

• Boston, United States
• Boston, United States
• Boston, United States
• Rochester, United States
• New York, United States
• New York, United States
• Nashville, United States
• Barcelona, Spain
• London, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Pathologic diagnosis of any solid tumor
* Incurable cancer, with disease progression following at least 1 therapy with no further standard treatment available in the opinion of the investigator.
* At least 1 evaluable lesion per RECIST criteria

Exclusion Criteria:

* Clinically unstable primary or metastatic CNS tumors
* Subjects with known diabetes
* QTc interval greater than 470 ms.